Drug Trial Radar · NCT01980888
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Last checked: Nov 19, 2026Latest source record: Nov 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
311
Actual
Start
Feb 5, 2014
Primary completion
May 30, 2016
Study completion Jun 16, 2016
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Nov 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the progression-free survival in participants with previously untreated chronic lymphocytic leukemia (CLL) who would otherwise be suitable for bendamustine and rituximab treatment as standard of care. An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).
Conditions
- Chronic Lymphocytic Leukemia
Interventions
IdelalisibDrug
150 mg tablet administered orally twice daily
BendamustineDrug
Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.
RituximabDrug
Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions
PlaceboDrug
Placebo to match idelalisib administered orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free SurvivalTime frame: Up to 22 months
Locations
91 sites in 13 countries. Site status is shown where the registry gives one.
St. Jude Heritage Healthcare Virginia K. Crosson Cancer Center
Fullerton, California
UCSD Moores Cancer Center
La Jolla, California
Central Coast Medical Oncology
Santa Maria, California
Georgetown University
Washington D.C., District of Columbia
Memorial Healthcare System
Hollywood, Florida
Cancer Specialists of North Florida
Jacksonville, Florida
Florida Cancer Specialists-South
Sarasota, Florida
Franciscan Physician Network Oncology & Hematology
Indianapolis, Indiana
Siouxland Hematology-Oncology Associates, LLP
Sioux City, Iowa
Center for Cancer and Blood Disorders
Bethesda, Maryland
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Hematology /Oncology Associates of Northern New Jersey
Morristown, New Jersey
Columbia University Medical Center
New York, New York
University of Rochester
Rochester, New York
Gabrail Cancer Center Research
Canton, Ohio
Sarah Cannon Research Institute
Cincinnati, Ohio
Signal Point Clinical Research Center
Middletown, Ohio
Saint Francis Hospital
Greenville, South Carolina
Sarah Cannon Research Institute
Nashville, Tennessee
Texas Oncology-Austin Midtown
Austin, Texas
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Fred Hutchinson Cancer Research Center
Seattle, Washington
St Vincent's Hospital, Sydney
Darlinghurst, New South Wales, Australia
Jarrett Street Specialist Centre
North Gosford, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital
Adelaide, South Australia, Australia
Flinders Medical Centre, Department of Haematology, Level 6
Bedford Park, South Australia, Australia
Ashford Cancer Centre Research
Kurralta Park, South Australia, Australia
Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Frankston Hospital
Frankston, Victoria, Australia
Barwon Health, University Hospital Geelong
Geelong, Victoria, Australia
Z N A Stuivenberg
Antwerp, Belgium
AZ Sint-Jan AV Brugge-Oostende
Bruges, Belgium
University Hospital Leuven
Leuven, Belgium
Cancercare Manitoba - Maccharles Unit
Winnipeg, Manitoba, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Hôpital du Sacré-Coeur de Montréal
Montreal, Quebec, Canada
CHU de Québec - Hôpital de l'Enfant-Jésus
Québec, Quebec, Canada
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.